Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Sundar Jagannath, Thierry Facon, Ashraf Z. Badros, Moshe Levy, Phillipe Moreau, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Iryrna Kriachok, Maria Gavriatopoulou , Halyna Pylypenko , Holger W. Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Chris P. VennerMamta Garg, Mercedes Gironella Mesa, Artur Jurczyszyn , Tadeusz Robak, Monica Galli, Craig Thomas Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Vesselina S. Goranova-Marinova , Jelena Sreten Bila, Eirini Katodritou , Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sebastian Grosicki, Paul G. Richardson

Research output: Contribution to journal › Meeting Abstract › peer-review

Fingerprint

Dive into the research topics of 'Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology